JUPITER NEUROSCIENCES, INC. (JUNS) AI Stock Summary

Snapshot

Jupiter Neurosciences is a clinical-stage biotech with essentially no revenue ($22K in FY 2025) and massive losses ($8.6M net loss). The company burns cash quickly ($5.4M in free cash flow annually) and holds only $3.8M in cash against $5.3M in debt, resulting in a cash runway of less than one month. This financial picture is strained, with a going-concern warning issued by auditors and a reverse stock split proposed to maintain its stock exchange listing. Shareholders have faced significant dilution, with the share count rising 20% in the last year.

What's Happening Right Now

• Tue 21st Jul '26 · Product Licensing: Jupiter signed a definitive agreement for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic, in a transaction valued up to $100 million.
• Tue 9th Jun '26 · Corporate Action: The company is seeking stockholder approval for a reverse stock split between 1-for-10 and 1-for-100 to regain compliance with Nasdaq listing rules.
• Thu 21st May '26 · Financing: Jupiter closed a $2.0 million registered direct offering, issuing over 7 million shares to extend cash runway and pay down debt.

Ownership

Institutions hold 3.3% of shares, while insiders hold 0.9%.

Bottom Line

This is a financially distressed micro-cap operating on fumes. With a cash runway of less than a month and an explicit going-concern warning, the immediate risk is insolvency rather than clinical trial results. The recent licensing deal for an MDMA therapeutic is a potential catalyst, but the company is simultaneously fighting to avoid delisting via a reverse stock split and diluting existing shareholders to stay afloat.